zinc finger protein 33BGenealiases: KOX2 · KOX31 · ZNF11B
Q-omics provides the consensus-scored ZNF33B profile across patient tissues and cancer cell-line models. ZNF33B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF33B is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ZNF33B RNA expression shows 21,183 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where ZNF33B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF33B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF33B survival associations across molecular data types. ZNF33B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF33B RNA expression–survival associations across cancer types. High ZNF33B expression shows unfavorable associations in ACC, but favorable associations in KIRC, MESO, BLCA, KIRP and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF33B RNA expression.
This table summarizes ZNF33B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF33B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF33B shows lower tumor expression in KICH, THCA and LUSC and higher tumor expression in LIHC, COAD and READ. The KICH box plot shows higher ZNF33B RNA expression in normal versus tumor tissue (log2 FC = −1.571, t-test p < 0.001).
This table shows molecular features associated with ZNF33B in patient tissues and cancer cell lines. In patient samples, ZNF33B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF33B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
